Citations

Showing 10 of 107966 citations.

Reply to “Implementing AI in clinical microbiology”: Key challenges ahead
Soliman, Amr , Marouf, Mohamed , Pancholi, Preeti , Graf, Erin, Soliman, Amr , Marouf, Mohamed , Graf, Erin H. , Parwani, Anil Vasdev

Mayo Clinic

American Journal of Clinical Pathology | February 21, 2025 | Volume: 163 | Issue: 6 | Pages: 950-950

10.1093/ajcp/aqaf005 | PMID 39982805 Get It

CHORIORETINITIS AFTER BACILLUS CALMETTE-GUERIN TREATMENT FOR BLADDER CANCER
Boopathiraj, Nithya , Wagner, Isabella V. , Powers, Ross, Mashayekhi, Arman , Wagner, Isabella V , Powers, Ross

Mayo Clinic

RETINAL Cases & Brief Reports | February 21, 2025 | Volume: 20 | Issue: 3 | Pages: 351-354

10.1097/icb.0000000000001736 | PMID 39983092 Get It

Purpose: To report a rare case of multifocal chorioretinitis subsequent to intravesical Bacillus Calmette-Guerin therapy for bladder cancer. Methods: Case report. Results: A 74-year-old man presented with ill-defined visual changes in his right eye, along with constitutional symptoms such as low-grade fever, chills with rigors, night sweats, headache, dry cough, memory problems, and unintentional weight loss. These symptoms occurred 11 months after receiving intravesical Bacillus Calmette-Guerin treatment for bladder cancer. His visual acuity in the right eye was 20/30. Examination of his right eye revealed multiple yellow white chorioretinal lesions, and optical coherence tomography imaging showed focal involvement of the choroid and overlying neurosensory retina. Blood-based testing using next-generation sequencing for detection of microbial cell free DNA (Karius test) was positive for Mycobacterium tuberculosis complex. The patient was treated with 12 months of triple therapy consisting of isoniazid, rifampin, and ethambutol. The chorioretinal lesions showed complete regression to flat scars, with no evidence of recurrence 15 months after discontinuation of systemic treatment. Conclusion: Despite being rare, the possibility of mycobacterial chorioretinitis should be considered in patients with new-onset visual symptoms after intravesical Bacillus Calmette-Guerin treatment for bladder cancer.
Diagnostic, survival, and tumor control outcomes of parapharyngeal space liposarcoma: a systematic review
Vasudevan, Srivatsa Surya , Kandrikar, Tiba Yamin , Janus, Jeffrey R. , Candelo, Estephanía

Mayo Clinic

Acta Oto-Laryngologica | February 21, 2025 | Volume: 145 | Issue: 4 | Pages: 348-354

10.1080/00016489.2025.2462688 | PMID 39982322 Get It

A Flipped Classroom Model to Enhance Simulation Education for Percutaneous Renal Surgery
Qi, Robert , Potretzke, Aaron M. , Liaw, Christine , Bearrick, Elizabeth , Ungerer, Garrett , Granberg, Candace F. , Koo, Kevin , Liaw, Christine W., Bearrick, Elizabeth N., Ungerer, Garrett N, Viers, Boyd R. , Koo, Kevin , Findlay, Bridget L.

Mayo Clinic

Urology Practice | February 21, 2025 | Volume: 12 | Issue: 2 | Pages: 187-190

10.1097/upj.0000000000000752 | PMID 39874476 Get It

A Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
Lewis, Kimberley , Balas, Michele C. , Stollings, Joanna L. , McNett, Molly , Girard, Timothy D., Chanques, Gérald , Kho, Michelle E. , Weinhouse, Gerald L., Brummel, Nathan E., Duby, Jeremiah J. , Hall-Melnychuk, Erin L., Krupp, Anna , Louzon, Patricia , Tate, Judith A. , Young, Bethany , Jennings, Ron, Hines, Anitra, Ross, Chris, Carayannopoulos, Kallirroi Laiya , Aldrich, Janet , Girard, Timothy D. , Girard, Timothy D , Pandharipande, Pratik , Brummel, Nathan E. , Chlan, Linda L. , Cordoza, Makayla L. , Gélinas, Céline , Aldrich, J. Matthew

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e711-e727

10.1097/ccm.0000000000006574 | PMID 39982143 Get It

RATIONALE: Critically ill adults are at risk for a variety of distressing and consequential symptoms both during and after an ICU stay. Management of these symptoms can directly influence outcomes. OBJECTIVES: The objective was to update and expand the Society of Critical Care Medicine’s 2018 Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. PANEL DESIGN: The interprofessional inclusive guidelines task force was composed of 24 individuals including nurses, physicians, pharmacists, physiotherapists, psychologists, and ICU survivors. The task force developed evidence-based recommendations using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Conflict-of-interest policies were strictly followed in all phases of the guidelines, including task force selection and voting. METHODS: The task force focused on five main content areas as they pertain to adult ICU patients: anxiety (new topic), agitation/sedation, delirium, immobility, and sleep disruption. Using the GRADE approach, we conducted a rigorous systematic review for each population, intervention, control, and outcome question to identify the best available evidence, statistically summarized the evidence, assessed the quality of evidence, and then performed the evidence-to-decision framework to formulate recommendations. RESULTS: The task force issued five statements related to the management of anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adults admitted to the ICU. In adult patients admitted to the ICU, the task force issued conditional recommendations to use dexmedetomidine over propofol for sedation, provide enhanced mobilization/rehabilitation over usual mobilization/rehabilitation, and administer melatonin. The task force was unable to issue recommendations on the administration of benzodiazepines to treat anxiety, and the use of antipsychotics to treat delirium. CONCLUSIONS: The guidelines task force provided recommendations for pharmacologic management of agitation/sedation and sleep, and nonpharmacologic management of immobility in critically ill adults. These recommendations are intended for consideration along with the patient’s clinical status.
Current perspectives in tackling glaucoma blindness
Bhartiya, Shibal, Ichhpujani, Parul , Wadhwani, Meenakshi

Mayo Clinic

Indian Journal of Ophthalmology | February 21, 2025 | Volume: 73 | Issue: Suppl 2 | Pages: S189-S196

10.4103/ijo.ijo_3280_23 | PMID 39982079 Get It

As a major reason for irreversible vision loss, glaucoma is a significant public health concern. Its multifactorial nature demands a nuanced understanding of its pathophysiology, risk factors, and management. An understanding, and continuous refinement, of diagnostic and therapeutic modalities, including pharmacological interventions, novel methods of drug delivery, and surgical techniques (including minimally invasive glaucoma surgeries) are critical. The advent of personalized medicine, genetic profiling, and innovative biomarkers for identifying susceptible individuals and tailoring treatment strategies may help prevent blindness and improve patient outcomes. Evaluation of the impact of lifestyle modifications and holistic approaches and integration of telemedicine and artificial intelligence in glaucoma management may revolutionize current glaucoma practice. In addressing the global challenge of glaucoma blindness, this narrative review highlights ongoing initiatives, public health policies, and community-based interventions. This includes raising awareness, enhancing early detection programs, and access to care, particularly in underserved populations.
Impact of valvulo-vascular haemodynamics on left ventricular remodelling and the prevalence of discordant moderate aortic stenosis
Ali, Mulham , Tastet, Lionel , Mogensen, Nils Sofus Borg , Diederichsen, Axel Cosmus Pyndt , Shen, Mylène, Arsenault, Marie , Møller, Jacob Eifer , Øvrehus, Kristian Altern , Bédard, Élisabeth , Lindholt, Jes S. , Lambrechtsen, Jess , Urbonavičienė, Gražina , Haujir, Amal , Pîbarot, Philippe , Clavel, Marie‐Annick , Diederichsen, Axel , Lindholt, Jes Sanddal , Steffensen, Flemming Hald , Urbonaviciene, Grazina , Haujir, Amal , Pellikka, Patricia A , Pibarot, Phillippe , Clavel, Marie-Annick , Dahl, Jordi S , Mortensen, Nils Sofus Borg , Øvrehus, Kristian , Lambrechtsen, Jess , Steffensen, Flemming Hald , Pellikka, Patricia A. , Dahl, Jordi S.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | February 21, 2025 | Volume: 26 | Issue: 4 | Pages: 686-694

10.1093/ehjci/jeaf021 | PMID 39981774 Get It

Abstract Aims This study aims to describe the prevalence of discordant mild/moderate aortic stenosis (AS) in a population-based study and to identify the mechanisms that lead to reduced stroke volume (SV) and discordant moderate AS. Methods and results Discordant high-gradient (HG)-mild AS, defined as AVA > 1.5 cm2 and mean pressure gradient (MG) of 20–40 mmHg, and discordant low-gradient (LG) moderate AS, defined as AVA 1.0–1.5 cm2 and MG < 20 mmHg, were assessed in 883 individuals from the DANCAVAS screening study with aortic valve calcification and 257 individuals form the PROGRESSA study excluding those with left ventricular (LV) ejection fraction < 50%. In the DANCAVAS cohort, 150 men had mild/moderate AS of which 34% had discordance between MG and AVA, representing 66% with moderate AS. Among 262 patients in the combined cohort, 39% had discordant LG-moderate AS and 6% discordant HG-mild AS. Compared with concordant mild and moderate AS, individuals with discordant LG-moderate AS were more likely to present with LV concentric remodelling geometry (26 vs. 33 vs. 45%, P < 0.001), increased valvulo-arterial impedance (3.3 ± 0.7 vs. 3.6 ± 0.5 vs. 4.1 ± 0.7 mmHg/mL/m2, P < 0.001), and reduced systemic arterial compliance (SAC) (0.74 ± 0.22 vs. 0.81 ± 0.22 vs. 0.64 ± 0.18 mL/m2/mmHg, P < 0.001). Factors associated with SV index were relative wall thickness, LV end-diastolic diameter index, SAC, and LV remodelling pattern. Conclusion Discordant moderate AS is common, accounting for two-thirds of patients with moderate AS in the general male population. Patients with discordant LG-moderate AS have predominantly a concentric remodelling pattern with reduced SV. Reduced SV index was associated with signs of reduced vascular compliance, suggesting that altered vascular properties drive differences in remodelling patterns and discordant moderate AS.
Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic
Saunders, David , Hellwig, Lydia D. , Pagani, Austin, Castro, Mauricio De , Poon, Lucas, Ehat, Nate, Heroy, Andrew , Libbus, Joya, Fox, Keiko , Kalra, Sachi, Black, John L. , Scherer, Steven E. , Moyer, Ann M. , Black, John Logan, Haigney, Mark C. , Kalra, Sachi, Arnold, Thomas B. , Turner, Clesson

Mayo Clinic

Pharmacogenomics | February 21, 2025 | Volume: 25 | Issue: 16-18 | Pages: 637-645

10.1080/14622416.2025.2466413 | PMID 39981562 Get It

Understanding monocyte-driven neuroinflammation in Alzheimer’s disease using human brain organoid microphysiological systems
Tian, Chunhui , Ao, Zheng , Cerneckis, Jonas , Cai, Hongwei , Niu, Henyao, Kim, Jungsu , Kanekiyo, Takahisa , Kim, Jungsu , Kanekiyo, Takahisa , Chen, Lei , Niu, Henyao, Takayama, Kazuo , Shi, Yanhong , Gu, Mingxia , Guo, Feng

Mayo Clinic

No container title available | February 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.02.16.638539 | PMID 40027735 Get It

Abstract Increasing evidence suggests that Alzheimer’s disease (AD) pathogenesis strongly correlates with neuroinflammation. Peripheral monocytes are crucial components of the human immune system that may play a role in neuroinflammation, but their contribution to AD pathogenesis is largely understudied partially due to the lack of appropriate human models. Here, we present human cortical organoid microphysiological systems (hCO-MPSs) for modeling dynamic AD neuroinflammation mediated by monocytes. By incorporating 3D printed devices into an existing cortical organoid protocol, 96 hCO-MPSs can be established with significantly reduced necrosis and hypoxia as well as enhanced viability within a commonly used 96 well plate, and each hCO-MPS consists of a doughnut-shaped hCO and a 3D printed device per well. Using this approach, monocytes from AD patients exhibit higher infiltration, decreased amyloid-beta (Aβ) clearance, and stronger inflammatory responses compared to monocytes from age-matched control donors. Moreover, pro-inflammatory effects such as elevated astrocyte activation and neuronal apoptosis were observed to be induced by AD monocytes. Furthermore, the significant increase in the expression of IL1B and CCL3, both at the transcriptional and protein levels, indicated the pivotal role of these cytokine and chemokine in monocyte-mediated AD neuroinflammation. Our findings provide insight for understanding monocytes’ role in AD pathogenesis, and the user-friendly MPS models we present are compatible with existing laboratory settings, highlighting their potential for modeling neuroinflammation and developing new therapeutics for various neuroinflammatory diseases.
Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single‐Institution Pilot Study
Britton, Cameron J. , Andrews, Jack R. , Arafa, Ali , Latuche, Laureano Rangel, Schulte, Phillip J. , Joshi, Vidhu B. , Karnes, R. Jeffrey , Kim, Yohan , Ahmed, Mohamed E. , Lucien, Fabrice

Mayo Clinic

The Prostate | February 21, 2025 | Volume: 85 | Issue: 6 | Pages: 594-602

10.1002/pros.24861 | PMID 39980247 Get It

ABSTRACTBackgroundCommercial biomarkers and multiparametric MRI (mpMRI) have been utilized to triage men with elevated prostate specific antigen (PSA) and determine patients most likely to harbor clinically‐significant prostate cancer (csPCa). We studied combinations of mpMRI, PSA‐based and novel extracellular vesicle (EV)‐based biomarkers to determine the optimal pre‐biopsy testing to predict csPCa at biopsy.MethodsMen presenting with elevated PSA (≥ 2 ng/mL) were prospectively enrolled and all men underwent clinically indicated mpMRI and blinded study blood draws to determine PSA, prostate health index (PHI) scoring, and EV serum levels. MRI‐fusion transperineal prostate biopsy was performed in all patients. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated, and receiver operator characteristic (ROC) curves were constructed. Bootstrapping analysis was performed to provide more accurate assessment of predictive abilities.ResultsUltimately, 175 consecutive men were prospectively enrolled. Median age in the study population was 65 years. Combinations of biomarkers and MRI demonstrated better predictive ability for csPCa on biopsy than individual modalities. Predictive ability was greatest for PHI density (PHID)‐mpMRI with an AUC of 0.86 (95% CI: 0.80–0.92) while combinations of PSA density ‐mpMRI (AUC: 0.81; 95% CI: 0.73–0.89) and STEAP1‐mpMRI (AUC: 0.77; 95% CI: 0.70–0.86) demonstrated similar ability to predict csPCa. The study is limited by small, predominantly white patient cohort and requires external validation.ConclusionsInclusion of prostate density with biomarkers increases prognostic ability for detecting csPCa. EV density can refine prediction of csPCa and in combination with PHID‐mpMRI leads to superior specificity, thereby decreasing unnecessary biopsies.